- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
IOL Chemicals & Pharmaceuticals has announced a board meeting on financial results for the quarter and half-year. Q4 revenue rose 4.7% to ₹527.8 Cr, EBITDA grew 17.1% to ₹67.5 Cr, and PAT increased 12.2% to ₹31.6 Cr YoY. Operationally, the company tripled Paracetamol capacity with a new 10,800 MTPA unit, expanded Clopidogrel Bisulphate capacity, and gained certifications for European and Chinese markets. Investments focus on capacity expansion and strategic consolidation, backed by strong backward integration.
All announcements from IOL Chemicals and Pharmaceuticals Limited